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OBJECTIVES: Develop and validate an epidemiological model to estimate the burden 
of post-menopausal osteoporosis (PMO) in terms of prevalence (women with low bone 
mineral density: BMD and/or a history of fracture), fracture incidence and attributable 
mortality up to 2020. METHODS: For validation purposes, the model was developed 
for Sweden (where the epidemiology of osteoporosis is well documented) and provided 
estimates from 1990. For each year of the study period, the “incident cohort”, deﬁned 
as women experiencing a ﬁrst osteoporotic fracture, was identiﬁed and run through 
a Markov model of 1-year cycles until 2020. Health states were based on the number 
of fractures (1, 2, 3) and death. Fracture by site was tracked for each health state 
(hip, vertebral, non-hip non vertebral). Transition probabilities reﬂected site-speciﬁc 
risk of death and subsequent fractures. BMD was included as a model output and 
reﬂected difference between women with and without a history of fracture. Model 
inputs included census from 1970 to 2020, incidence of fracture, relative risk of sub-
sequent fractures based on prior fracture, relative risk of death following a fracture 
by site, mean and standard deviation BMD by age. RESULTS: Model predictions 
averaged across age groups estimated the incidence of hip, vertebral and other osteo-
porotic fractures within a 5% margin of error compared to published data. Between 
2010 and 2020, the number of women aged 50 years is expected to increase by 9% 
whereas the number of osteoporotic fractures and women suffering from PMO (T-
score  2.5 or history of fracture) is expected to increase by 11% and 12% respec-
tively. CONCLUSIONS: A PMO disease model was developed and validated against 
Swedish data. This model can be adapted to other countries to assess the burden of 
illness and used to estimate the budgetary impact of therapies that reduce bone loss.
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OBJECTIVES: To observe, under actual conditions of use, the effect obtained, in the 
context of management of knee osteoarthritis, combining a prescription of Avian ACS 
(1 g/day) between 2 courses of treatment of 3 injections of hyaluronic acid spaced out 
by a maximum of 12 months. METHODS: Pragmatic, longitudinal and prospective 
follow-up carried out by rheumatologists in the context of their daily professional 
activities RESULTS: The results presented come from a preliminary analysis concern-
ing the ﬁrst patients assessable at 6 months. Forty-ﬁve percent of the patients are 
treated with hyaluronic acid for left knee osteoarthritis and 52% are treated with 
hyaluronic acid for right knee osteoarthritis (3% treated for both). Average pain 
during activities of daily living was measured by means of a visual analogue scale. It 
is 53.28 o 20.83 at inclusion. At 18 weeks, this same average pain measured under 
the same conditions is 37.96 o 17.17. A third measurement at 24 weeks situates it at 
35.62 o 17.95. Pain during activities of daily living is signiﬁcantly reduced between 
inclusion and week 18 (p  0.0056). The average reduction in pain during activities 
of daily living measured between inclusion and 6 months is also signiﬁcant (p  0.001). 
Accordingly, the reduction obtained in 6 months is 33%. CONCLUSIONS: Our 
study, which assesses the effect on pain obtained in the context of management of 
subjects with knee osteoarthritis, combining a prescription of Structum® (1 g/day) 
between two courses of treatment of three injections of Structovial®, showed a reduc-
tion in pain during activities of daily living. This reduction in pain, which is signiﬁcant 
at 18 weeks, then perpetuated at 6 months, shows the relevance of the treatment 
protocol used by the doctors.
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OBJECTIVES: Verteporﬁn is the ﬁrst product approved for neovascular age-related 
macular degeneration (AMD). The severity of AMD, the innovative aspect of Verte-
porﬁn and its ﬁnancial implications motivated French Authorities to request a real life 
drug utilization study. To describe in France patients treated by Verteporﬁn for neo-
vascular AMD, their visual acuity changes (responders: VA loss 15 letters) and 
number of needed treatments. METHODS: Observational, prospective, multi-center 
study with two parts: a registry for all patients treated by Verteporﬁn for AMD or 
other diseases; a cohort with two years follow-up of neovascular AMD patients treated 
by Verteporﬁn. RESULTS: In the registry, 96.8% of patients were treated by Verte-
porﬁn in its approved indication.Iin the cohort, from May 2004 to December 2006, 
438 patients were included (39 ophthalmologists). Population was 78.3 o 7.6 years, 
67.6% women. At baseline, 58.2% of patients had bilateral AMD. Diagnosis was 
done 9.0 months ago. In the study eye, lesion type was predominately classic in 270 
patients (61.6%) and occult in 168 patients (38.4%); 35.5% of patients were previ-
ously treated by Verteporﬁn. A total of 65.5% of population was retreated by Verte-
porﬁn during the follow-up, the ﬁrst retreatment was at 4.3 months from baseline; 
average number of treatments was 2.21 (predominately classic: 2.50; occult: 0.80). 
Comparing to year 1, proportion of patients treated by Verteporﬁn decreased in the 
second year: 64.4% vs 11.5%. At two years, responder rates were 67.8% in whole 
naïve population, 67.2% and 68.2% for predominately classic and occult respectively. 
In average, visual acuity change was 7 letters (from 43 to 36 letters). No unexpected 
adverse event was observed. CONCLUSIONS: This study conﬁrms the efﬁcacy of 
Verteporﬁn in real life setting but treatment rate was lower than in pivotal studies.
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OBJECTIVES: To compare the clinical outcomes of different MIOLs using a meta-
analysis based on the available information reported in the international literature. 
METHODS: All comparative clinical trials including at least one MIOL were extracted 
from the literature. Patients had to have surgery for either cataract or presbyopia. 
Clinical outcomes included uncorrected near and distance visual acuity (UNVA, 
UDVA in LogMAR), spectacle independence and halos. Random effects meta-analyses 
were conducted to compare outcomes for different types of implants. RESULTS: 
Twenty papers were identiﬁed with 11 monofocal IOLs and 35 MIOLs (19 diffractives 
including 12 ReSTORs, 14 refractives and 2 accommodatives). In comparison to 
monofocal IOLs, MIOLs had better UDVA (0.165 vs. 0.093, p  0.001) and better 
UNVA (0.47 vs. 0.14, p  0.0001) resulting in a higher spectacle independence inci-
dence rate (IRR  3.62, P  0.0001). In comparison to refractive MIOLs, diffractive 
MIOLs had similar UDVA (0.105 vs. 0.085, p  0.78), and better UNVA (0.22 vs. 
0.082, p  0.0001) resulting in a higher spectacle independence incidence rate (IRR  
1.75, P  0.001). In comparison to other MIOLs, ReSTOR had better UDVA (0.067 
vs. 0.109, p  0.0001), and better UNVA (0.064 vs. 0.184, p  0.006) resulting in a 
higher spectacle independence incidence rate (IRR  2.04, P  0.004). We found no 
statistically signiﬁcant differences in halo incidence rates for different types of implants. 
CONCLUSIONS: MIOLs provide better UNVA and UDVA than monofocal IOLs, 
which lessens the need for spectacles. The design of the MIOL might play a role in 
post-surgical outcomes of different models. ReSTOR, a diffractive MIOL, showed 
better UNVA, UDVA and higher rates of spectacle independence than the other 
MIOLs.
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OBJECTIVES: The objective of this analysis was to compare treatment persistency of 
three treatment sequences: Xalatan-Xalacom (XX), Lumigan-Ganfort (LG) and Trav-
atan-DuoTrav (TD) according to data collected in the United-Kingdom General Prac-
titioner Research Database (UK-GPRD). METHODS: Patients with a diagnosis of 
ocular hypertension or glaucoma, or treated with a topical treatment, surgery or laser 
were selected. Patients with sequence prescription of XX, LG and TD were selected. 
A treatment failure was deﬁned as a prescription change (adding or removing a topical 
treatment). Time to treatment failure was compared using Wilcoxon test applied to 
survival curves. Adjustment on confounding variables was performed with the pro-
pensity score method using a logistic stepwise regression. RESULTS: 1562 patients 
were treated by XX, 110 by LG and 114 by TD. Mean age was 75 years and the sex-
ratio was close to 1 male/ 1 female. No demographic or co-morbidity differences 
between treatment sequences were observed. At 30 months, 66.5% of the XX patients 
had not failed (remain with the same treatment sequence), versus 60.5% of the LG 
and 75.1% of the TD patients (Wilcoxon, P  0.005). At 60 months these results 
became, 42.2%, 49.9%, and 52.0%, respectively (Wilcoxon, P  0.04). Adjustment 
for confounding variables did not change these estimates. CONCLUSIONS: Accord-
ing to the UK-GPRD information, the Travatan-DuoTrav treatment sequence was 
associated with longer treatment persistence
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5% CREAM FOR THE TREATMENT OF ACTINIC KERATOSES
Walczak J, Nogas G, Chmiel M, Kowalska M
Arcana Institute, Cracow, Poland
OBJECTIVES: The aim of the review was to evaluate the efﬁcacy and safety of 
imiquimod 5% cream compared with vehicle for the treatment of actinic keratoses. 
METHODS: The analysis was performed in accordance with the rules of systematic 
review, based on the Cochrane Collaboration (Cochrane Reviewer’s Handbook) 
guidelines and the Health Technology Assessment Agency in Poland (AOTM) recom-
mendations. RESULTS: Imiquimod 5 percent cream versus vehicle in short time 
